JW Shinyak Corporation (KOSDAQ:067290)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,025.00
+20.00 (1.00%)
At close: Apr 23, 2026
Market Cap117.33B +66.8%
Revenue (ttm)81.04B -12.9%
Net Income15.66B +208.1%
EPS245.00 +295.2%
Shares Out55.87M
PE Ratio8.57
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume384,389
Average Volume689,322
Open2,025.00
Previous Close2,005.00
Day's Range1,991.00 - 2,050.00
52-Week Range1,288.57 - 2,670.00
Beta0.84
RSI53.72
Earnings DateMay 14, 2026

About JW Shinyak

JW Shinyak Corporation engages in the research, development, production, and sale of medicines and medical supplies in South Korea. It offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. The company also develops prostate cancer treatment, liver cancer treatment, rheum... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 1981
Employees 183
Stock Exchange KOSDAQ
Ticker Symbol 067290
Full Company Profile

Financial Performance

In 2025, JW Shinyak's revenue was 81.04 billion, a decrease of -12.87% compared to the previous year's 93.01 billion. Earnings were 15.66 billion, an increase of 208.11%.

Financial Statements